 Small Cell Lung Carcinoma
"Small Cell Lung Carcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
| Descriptor ID |
D055752
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.624 C08.381.540.140.750 C08.785.520.100.220.750
|
| Concept/Terms |
Small Cell Lung Carcinoma- Small Cell Lung Carcinoma
- Small Cell Lung Cancer
- Oat Cell Lung Cancer
- Small Cell Cancer Of The Lung
- Carcinoma, Small Cell Lung
- Oat Cell Carcinoma of Lung
|
Below are MeSH descriptors whose meaning is more general than "Small Cell Lung Carcinoma".
Below are MeSH descriptors whose meaning is more specific than "Small Cell Lung Carcinoma".
This graph shows the total number of publications written about "Small Cell Lung Carcinoma" by people in this website by year, and whether "Small Cell Lung Carcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 3 | 0 | 3 | | 2010 | 1 | 1 | 2 | | 2011 | 4 | 0 | 4 | | 2012 | 4 | 0 | 4 | | 2013 | 3 | 0 | 3 | | 2014 | 3 | 0 | 3 | | 2015 | 1 | 1 | 2 | | 2016 | 6 | 1 | 7 | | 2017 | 8 | 1 | 9 | | 2018 | 5 | 0 | 5 | | 2019 | 4 | 0 | 4 | | 2020 | 5 | 0 | 5 | | 2021 | 6 | 0 | 6 | | 2022 | 4 | 0 | 4 | | 2023 | 6 | 0 | 6 | | 2024 | 5 | 0 | 5 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Small Cell Lung Carcinoma" by people in Profiles.
-
Savchuk S, Gentry KM, Wang W, Carleton E, Biagi-Junior CAO, Luthria K, Yalçin B, Ni L, Farnsworth HC, Davis RA, Drexler R, Melms JC, Liu Y, Acosta-Alvarez L, Hartmann GG, Pavarino EC, LaBelle J, Woo PJ, Toland AM, Qu F, Kim YS, Filbin MG, Krasnow MA, Ligon KL, Izar B, Sage J, Sabatini BL, Monje M, Venkatesh HS. Neuronal activity-dependent mechanisms of small cell lung cancer pathogenesis. Nature. 2025 Oct; 646(8087):1232-1242.
-
Sun NY, Kumar S, Kim YS, Varghese D, Mendoza A, Nguyen R, Okada R, Reilly K, Widemann B, Pommier Y, Elloumi F, Dhall A, Taniyama D, Patel M, Aber E, Contreras CF, Kaplan RN, Kiseljak-Vassiliades K, Wierman ME, Martinez D, Pogoriler J, Hamilton AK, Diskin SJ, Maris JM, Robey RW, Gottesman MM, Del Rivero J, Roper N. Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. Nat Commun. 2025 Jul 01; 16(1):5511.
-
Madan R, El Alam RH, Walker CM, Bang TJ, Bartel TB, Batra K, Brixey AG, Christensen JD, Cox CW, Gonzalez AV, Little BP, Lui NS, Maxfield H, Moore WH, Qin A, Shroff GS, Yasufuku K, Chung JH. ACR Appropriateness Criteria® Lung Cancer-Surveillance After Therapy. J Am Coll Radiol. 2025 May; 22(5S):S319-S342.
-
Hunting JC, Price SN, Faucheux AT, Olson E, Elko CA, Quattlebaum A, Ruiz J, Lycan TW. Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study. Immunotherapy. 2025 01; 17(1):19-24.
-
Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. J Thorac Oncol. 2025 Mar; 20(3):383-394.
-
Concannon KF, Glisson BS, Doebele RC, Huang C, Marotti M, Camidge DR, Heymach JV. A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Nov; 25(7):601-611.
-
Desai P, Takahashi N, Kumar R, Nichols S, Malin J, Hunt A, Schultz C, Cao Y, Tillo D, Nousome D, Chauhan L, Sciuto L, Jordan K, Rajapakse V, Tandon M, Lissa D, Zhang Y, Kumar S, Pongor L, Singh A, Schroder B, Sharma AK, Chang T, Vilimas R, Pinkiert D, Graham C, Butcher D, Warner A, Sebastian R, Mahon M, Baker K, Cheng J, Berger A, Lake R, Abel M, Krishnamurthy M, Chrisafis G, Fitzgerald P, Nirula M, Goyal S, Atkinson D, Bateman NW, Abulez T, Nair G, Apolo A, Guha U, Karim B, El Meskini R, Ohler ZW, Jolly MK, Schaffer A, Ruppin E, Kleiner D, Miettinen M, Brown GT, Hewitt S, Conrads T, Thomas A. Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities. Cell Rep Med. 2024 Jun 18; 5(6):101610.
-
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, Paz-Ares L, Bunn PA. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. J Clin Oncol. 2024 Jul 01; 42(19):2317-2326.
-
Stinchcombe TE, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Altorki N. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Apr 01; 42(10):1110-1113.
-
Shen M, Liu S, Toland A, Hsu EC, Hartono AB, Alabi BR, Aslan M, Nguyen HM, Sessions CJ, Nolley R, Shi C, Huang J, Brooks JD, Corey E, Stoyanova T. ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype. Br J Cancer. 2023 11; 129(11):1818-1828.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|